nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP2E1—Fingolimod—multiple sclerosis	0.101	0.149	CbGbCtD
Fluvoxamine—CYP2D6—Fingolimod—multiple sclerosis	0.048	0.0709	CbGbCtD
Fluvoxamine—CYP2E1—Mitoxantrone—multiple sclerosis	0.0473	0.07	CbGbCtD
Fluvoxamine—ABCB1—Methylprednisolone—multiple sclerosis	0.0328	0.0485	CbGbCtD
Fluvoxamine—CYP1A1—Dexamethasone—multiple sclerosis	0.0318	0.047	CbGbCtD
Fluvoxamine—CYP3A4—Fingolimod—multiple sclerosis	0.0305	0.0451	CbGbCtD
Fluvoxamine—CYP3A7—Dexamethasone—multiple sclerosis	0.0254	0.0376	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0254	0.0376	CbGbCtD
Fluvoxamine—CYP2C19—Prednisone—multiple sclerosis	0.0246	0.0364	CbGbCtD
Fluvoxamine—CYP2E1—Dexamethasone—multiple sclerosis	0.0245	0.0363	CbGbCtD
Fluvoxamine—CYP2B6—Dexamethasone—multiple sclerosis	0.0242	0.0358	CbGbCtD
Fluvoxamine—ABCB1—Mitoxantrone—multiple sclerosis	0.0239	0.0354	CbGbCtD
Fluvoxamine—ABCB1—Betamethasone—multiple sclerosis	0.0213	0.0315	CbGbCtD
Fluvoxamine—ABCB1—Prednisolone—multiple sclerosis	0.021	0.0311	CbGbCtD
Fluvoxamine—ABCB1—Prednisone—multiple sclerosis	0.0199	0.0294	CbGbCtD
Fluvoxamine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0197	0.0291	CbGbCtD
Fluvoxamine—CYP3A5—Dexamethasone—multiple sclerosis	0.0191	0.0282	CbGbCtD
Fluvoxamine—CYP2C19—Dexamethasone—multiple sclerosis	0.0154	0.0227	CbGbCtD
Fluvoxamine—CYP3A4—Triamcinolone—multiple sclerosis	0.0149	0.022	CbGbCtD
Fluvoxamine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0143	0.0212	CbGbCtD
Fluvoxamine—CYP2C9—Dexamethasone—multiple sclerosis	0.0128	0.0189	CbGbCtD
Fluvoxamine—CYP3A4—Betamethasone—multiple sclerosis	0.0128	0.0189	CbGbCtD
Fluvoxamine—CYP3A4—Prednisolone—multiple sclerosis	0.0126	0.0186	CbGbCtD
Fluvoxamine—ABCB1—Dexamethasone—multiple sclerosis	0.0124	0.0183	CbGbCtD
Fluvoxamine—CYP3A4—Prednisone—multiple sclerosis	0.0119	0.0176	CbGbCtD
Fluvoxamine—CYP2D6—Dexamethasone—multiple sclerosis	0.0117	0.0173	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—multiple sclerosis	0.00997	0.0147	CbGbCtD
Fluvoxamine—CYP3A4—Dexamethasone—multiple sclerosis	0.00743	0.011	CbGbCtD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000131	0.00264	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.00013	0.00262	CbGpPWpGaD
Fluvoxamine—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000125	0.00251	CbGpPWpGaD
Fluvoxamine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000125	0.0025	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000124	0.0025	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000123	0.00247	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000123	0.00247	CbGpPWpGaD
Fluvoxamine—SLC6A3—Monoamine Transport—TNF—multiple sclerosis	0.000122	0.00245	CbGpPWpGaD
Fluvoxamine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000122	0.000445	CcSEcCtD
Fluvoxamine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000122	0.000445	CcSEcCtD
Fluvoxamine—Epistaxis—Methotrexate—multiple sclerosis	0.000122	0.000445	CcSEcCtD
Fluvoxamine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000122	0.000445	CcSEcCtD
Fluvoxamine—Paraesthesia—Prednisolone—multiple sclerosis	0.000122	0.000445	CcSEcCtD
Fluvoxamine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000122	0.00245	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000122	0.00245	CbGpPWpGaD
Fluvoxamine—Tachycardia—Triamcinolone—multiple sclerosis	0.000122	0.000444	CcSEcCtD
Fluvoxamine—Mental disorder—Prednisone—multiple sclerosis	0.000122	0.000444	CcSEcCtD
Fluvoxamine—Nausea—Azathioprine—multiple sclerosis	0.000122	0.000444	CcSEcCtD
Fluvoxamine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000121	0.000443	CcSEcCtD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000121	0.00244	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000121	0.00244	CbGpPWpGaD
Fluvoxamine—Malnutrition—Prednisone—multiple sclerosis	0.000121	0.000441	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000121	0.00044	CcSEcCtD
Fluvoxamine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000121	0.00044	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00012	0.000439	CcSEcCtD
Fluvoxamine—Convulsion—Dexamethasone—multiple sclerosis	0.00012	0.000439	CcSEcCtD
Fluvoxamine—Convulsion—Betamethasone—multiple sclerosis	0.00012	0.000439	CcSEcCtD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00012	0.00242	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00012	0.00242	CbGpPWpGaD
Fluvoxamine—Hypertension—Betamethasone—multiple sclerosis	0.00012	0.000437	CcSEcCtD
Fluvoxamine—Hypertension—Dexamethasone—multiple sclerosis	0.00012	0.000437	CcSEcCtD
Fluvoxamine—Asthenia—Mitoxantrone—multiple sclerosis	0.000119	0.000433	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000118	0.00238	CbGpPWpGaD
Fluvoxamine—Myalgia—Betamethasone—multiple sclerosis	0.000118	0.000431	CcSEcCtD
Fluvoxamine—Myalgia—Dexamethasone—multiple sclerosis	0.000118	0.000431	CcSEcCtD
Fluvoxamine—Anxiety—Dexamethasone—multiple sclerosis	0.000118	0.00043	CcSEcCtD
Fluvoxamine—Anxiety—Betamethasone—multiple sclerosis	0.000118	0.00043	CcSEcCtD
Fluvoxamine—Discomfort—Betamethasone—multiple sclerosis	0.000117	0.000426	CcSEcCtD
Fluvoxamine—Discomfort—Dexamethasone—multiple sclerosis	0.000117	0.000426	CcSEcCtD
Fluvoxamine—Haemoglobin—Methotrexate—multiple sclerosis	0.000117	0.000425	CcSEcCtD
Fluvoxamine—Hypotension—Methylprednisolone—multiple sclerosis	0.000116	0.000425	CcSEcCtD
Fluvoxamine—Pain—Prednisolone—multiple sclerosis	0.000116	0.000423	CcSEcCtD
Fluvoxamine—Hepatitis—Methotrexate—multiple sclerosis	0.000116	0.000423	CcSEcCtD
Fluvoxamine—Haemorrhage—Methotrexate—multiple sclerosis	0.000116	0.000423	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—multiple sclerosis	0.000115	0.00042	CcSEcCtD
Fluvoxamine—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000115	0.00231	CbGpPWpGaD
Fluvoxamine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000115	0.000418	CcSEcCtD
Fluvoxamine—Vision blurred—Prednisone—multiple sclerosis	0.000114	0.000416	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000114	0.00229	CbGpPWpGaD
Fluvoxamine—Urethral disorder—Methotrexate—multiple sclerosis	0.000114	0.000415	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000114	0.000415	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000113	0.000414	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000113	0.000413	CcSEcCtD
Fluvoxamine—Oedema—Betamethasone—multiple sclerosis	0.000113	0.000413	CcSEcCtD
Fluvoxamine—Oedema—Dexamethasone—multiple sclerosis	0.000113	0.000413	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000113	0.000413	CcSEcCtD
Fluvoxamine—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000113	0.00228	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000113	0.000413	CcSEcCtD
Fluvoxamine—Insomnia—Triamcinolone—multiple sclerosis	0.000113	0.000412	CcSEcCtD
Fluvoxamine—Insomnia—Methylprednisolone—multiple sclerosis	0.000113	0.000411	CcSEcCtD
Fluvoxamine—Infection—Dexamethasone—multiple sclerosis	0.000112	0.000411	CcSEcCtD
Fluvoxamine—Infection—Betamethasone—multiple sclerosis	0.000112	0.000411	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Prednisone—multiple sclerosis	0.000112	0.000409	CcSEcCtD
Fluvoxamine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000112	0.000409	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000112	0.000408	CcSEcCtD
Fluvoxamine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000112	0.000408	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—multiple sclerosis	0.000112	0.000408	CcSEcCtD
Fluvoxamine—Anaemia—Prednisone—multiple sclerosis	0.000112	0.000408	CcSEcCtD
Fluvoxamine—Shock—Dexamethasone—multiple sclerosis	0.000111	0.000407	CcSEcCtD
Fluvoxamine—Shock—Betamethasone—multiple sclerosis	0.000111	0.000407	CcSEcCtD
Fluvoxamine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000111	0.000406	CcSEcCtD
Fluvoxamine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000111	0.000405	CcSEcCtD
Fluvoxamine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000111	0.000405	CcSEcCtD
Fluvoxamine—Agitation—Prednisone—multiple sclerosis	0.000111	0.000405	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000111	0.000405	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000111	0.000405	CcSEcCtD
Fluvoxamine—Tachycardia—Betamethasone—multiple sclerosis	0.00011	0.000403	CcSEcCtD
Fluvoxamine—Tachycardia—Dexamethasone—multiple sclerosis	0.00011	0.000403	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.00011	0.00222	CbGpPWpGaD
Fluvoxamine—Angioedema—Prednisone—multiple sclerosis	0.00011	0.000403	CcSEcCtD
Fluvoxamine—Dyspepsia—Triamcinolone—multiple sclerosis	0.00011	0.000401	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—multiple sclerosis	0.00011	0.0004	CcSEcCtD
Fluvoxamine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00011	0.0004	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000109	0.000399	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000109	0.000399	CcSEcCtD
Fluvoxamine—Malaise—Prednisone—multiple sclerosis	0.000109	0.000398	CcSEcCtD
Fluvoxamine—Vertigo—Prednisone—multiple sclerosis	0.000109	0.000396	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—multiple sclerosis	0.000108	0.000396	CcSEcCtD
Fluvoxamine—Syncope—Prednisone—multiple sclerosis	0.000108	0.000395	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—multiple sclerosis	0.000108	0.000395	CcSEcCtD
Fluvoxamine—Anorexia—Betamethasone—multiple sclerosis	0.000108	0.000394	CcSEcCtD
Fluvoxamine—Anorexia—Dexamethasone—multiple sclerosis	0.000108	0.000394	CcSEcCtD
Fluvoxamine—Urticaria—Prednisolone—multiple sclerosis	0.000108	0.000393	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000108	0.000393	CcSEcCtD
Fluvoxamine—Fatigue—Triamcinolone—multiple sclerosis	0.000108	0.000393	CcSEcCtD
Fluvoxamine—SLC6A3—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000107	0.00216	CbGpPWpGaD
Fluvoxamine—Fatigue—Methylprednisolone—multiple sclerosis	0.000107	0.000392	CcSEcCtD
Fluvoxamine—Pain—Triamcinolone—multiple sclerosis	0.000107	0.000389	CcSEcCtD
Fluvoxamine—Loss of consciousness—Prednisone—multiple sclerosis	0.000106	0.000388	CcSEcCtD
Fluvoxamine—Hypotension—Betamethasone—multiple sclerosis	0.000106	0.000386	CcSEcCtD
Fluvoxamine—Hypotension—Dexamethasone—multiple sclerosis	0.000106	0.000386	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000106	0.00213	CbGpPWpGaD
Fluvoxamine—Angiopathy—Methotrexate—multiple sclerosis	0.000105	0.000384	CcSEcCtD
Fluvoxamine—Vomiting—Mitoxantrone—multiple sclerosis	0.000105	0.000384	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000105	0.00211	CbGpPWpGaD
Fluvoxamine—Convulsion—Prednisone—multiple sclerosis	0.000105	0.000382	CcSEcCtD
Fluvoxamine—Hypertension—Prednisone—multiple sclerosis	0.000104	0.000381	CcSEcCtD
Fluvoxamine—Rash—Mitoxantrone—multiple sclerosis	0.000104	0.000381	CcSEcCtD
Fluvoxamine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000104	0.00038	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—multiple sclerosis	0.000104	0.00038	CcSEcCtD
Fluvoxamine—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000104	0.00209	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000104	0.00209	CbGpPWpGaD
Fluvoxamine—Headache—Mitoxantrone—multiple sclerosis	0.000104	0.000378	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000103	0.000376	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000103	0.000376	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000103	0.00207	CbGpPWpGaD
Fluvoxamine—Myalgia—Prednisone—multiple sclerosis	0.000103	0.000375	CcSEcCtD
Fluvoxamine—Arthralgia—Prednisone—multiple sclerosis	0.000103	0.000375	CcSEcCtD
Fluvoxamine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000103	0.000375	CcSEcCtD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000103	0.00206	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000103	0.00206	CbGpPWpGaD
Fluvoxamine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000103	0.000374	CcSEcCtD
Fluvoxamine—Anxiety—Prednisone—multiple sclerosis	0.000102	0.000374	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—multiple sclerosis	0.000102	0.000374	CcSEcCtD
Fluvoxamine—Insomnia—Dexamethasone—multiple sclerosis	0.000102	0.000374	CcSEcCtD
Fluvoxamine—Insomnia—Betamethasone—multiple sclerosis	0.000102	0.000374	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000102	0.000372	CcSEcCtD
Fluvoxamine—Paraesthesia—Betamethasone—multiple sclerosis	0.000102	0.000371	CcSEcCtD
Fluvoxamine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000102	0.000371	CcSEcCtD
Fluvoxamine—Discomfort—Prednisone—multiple sclerosis	0.000102	0.000371	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—multiple sclerosis	0.000102	0.000371	CcSEcCtD
Fluvoxamine—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000101	0.00204	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000101	0.00203	CbGpPWpGaD
Fluvoxamine—Malnutrition—Methotrexate—multiple sclerosis	0.000101	0.000368	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000101	0.00203	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Prednisolone—multiple sclerosis	0.0001	0.000365	CcSEcCtD
Fluvoxamine—Dyspepsia—Dexamethasone—multiple sclerosis	9.97e-05	0.000364	CcSEcCtD
Fluvoxamine—Dyspepsia—Betamethasone—multiple sclerosis	9.97e-05	0.000364	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	9.94e-05	0.002	CbGpPWpGaD
Fluvoxamine—Urticaria—Triamcinolone—multiple sclerosis	9.91e-05	0.000362	CcSEcCtD
Fluvoxamine—Urticaria—Methylprednisolone—multiple sclerosis	9.89e-05	0.000361	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—multiple sclerosis	9.89e-05	0.000361	CcSEcCtD
Fluvoxamine—Body temperature increased—Triamcinolone—multiple sclerosis	9.86e-05	0.00036	CcSEcCtD
Fluvoxamine—Oedema—Prednisone—multiple sclerosis	9.86e-05	0.00036	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Prednisone—multiple sclerosis	9.86e-05	0.00036	CcSEcCtD
Fluvoxamine—Abdominal pain—Methylprednisolone—multiple sclerosis	9.84e-05	0.000359	CcSEcCtD
Fluvoxamine—Decreased appetite—Dexamethasone—multiple sclerosis	9.84e-05	0.000359	CcSEcCtD
Fluvoxamine—Decreased appetite—Betamethasone—multiple sclerosis	9.84e-05	0.000359	CcSEcCtD
Fluvoxamine—Nausea—Mitoxantrone—multiple sclerosis	9.82e-05	0.000359	CcSEcCtD
Fluvoxamine—Infection—Prednisone—multiple sclerosis	9.79e-05	0.000357	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	9.77e-05	0.000357	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	9.77e-05	0.000357	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—multiple sclerosis	9.77e-05	0.000356	CcSEcCtD
Fluvoxamine—Fatigue—Dexamethasone—multiple sclerosis	9.76e-05	0.000356	CcSEcCtD
Fluvoxamine—Fatigue—Betamethasone—multiple sclerosis	9.76e-05	0.000356	CcSEcCtD
Fluvoxamine—Shock—Prednisone—multiple sclerosis	9.7e-05	0.000354	CcSEcCtD
Fluvoxamine—Pain—Betamethasone—multiple sclerosis	9.68e-05	0.000353	CcSEcCtD
Fluvoxamine—Pain—Dexamethasone—multiple sclerosis	9.68e-05	0.000353	CcSEcCtD
Fluvoxamine—Nervous system disorder—Prednisone—multiple sclerosis	9.67e-05	0.000353	CcSEcCtD
Fluvoxamine—Tachycardia—Prednisone—multiple sclerosis	9.62e-05	0.000351	CcSEcCtD
Fluvoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.61e-05	0.00193	CbGpPWpGaD
Fluvoxamine—Hyperhidrosis—Prednisone—multiple sclerosis	9.53e-05	0.000348	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—multiple sclerosis	9.51e-05	0.000347	CcSEcCtD
Fluvoxamine—Anorexia—Prednisone—multiple sclerosis	9.4e-05	0.000343	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—multiple sclerosis	9.37e-05	0.000342	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—multiple sclerosis	9.33e-05	0.000341	CcSEcCtD
Fluvoxamine—Feeling abnormal—Dexamethasone—multiple sclerosis	9.33e-05	0.000341	CcSEcCtD
Fluvoxamine—Feeling abnormal—Betamethasone—multiple sclerosis	9.33e-05	0.000341	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Betamethasone—multiple sclerosis	9.26e-05	0.000338	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	9.26e-05	0.000338	CcSEcCtD
Fluvoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.23e-05	0.00186	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Triamcinolone—multiple sclerosis	9.19e-05	0.000336	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methylprednisolone—multiple sclerosis	9.17e-05	0.000335	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—multiple sclerosis	9.1e-05	0.000332	CcSEcCtD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	9.08e-05	0.00183	CbGpPWpGaD
Fluvoxamine—Vertigo—Methotrexate—multiple sclerosis	9.07e-05	0.000331	CcSEcCtD
Fluvoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.04e-05	0.00182	CbGpPWpGaD
Fluvoxamine—Leukopenia—Methotrexate—multiple sclerosis	9.04e-05	0.00033	CcSEcCtD
Fluvoxamine—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.02e-05	0.00181	CbGpPWpGaD
Fluvoxamine—Urticaria—Betamethasone—multiple sclerosis	8.99e-05	0.000328	CcSEcCtD
Fluvoxamine—Urticaria—Dexamethasone—multiple sclerosis	8.99e-05	0.000328	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	8.98e-05	0.000328	CcSEcCtD
Fluvoxamine—Dizziness—Prednisolone—multiple sclerosis	8.97e-05	0.000327	CcSEcCtD
Fluvoxamine—Asthenia—Triamcinolone—multiple sclerosis	8.95e-05	0.000327	CcSEcCtD
Fluvoxamine—Body temperature increased—Dexamethasone—multiple sclerosis	8.95e-05	0.000327	CcSEcCtD
Fluvoxamine—Abdominal pain—Betamethasone—multiple sclerosis	8.95e-05	0.000327	CcSEcCtD
Fluvoxamine—Body temperature increased—Betamethasone—multiple sclerosis	8.95e-05	0.000327	CcSEcCtD
Fluvoxamine—Abdominal pain—Dexamethasone—multiple sclerosis	8.95e-05	0.000327	CcSEcCtD
Fluvoxamine—Asthenia—Methylprednisolone—multiple sclerosis	8.93e-05	0.000326	CcSEcCtD
Fluvoxamine—Insomnia—Prednisone—multiple sclerosis	8.92e-05	0.000325	CcSEcCtD
Fluvoxamine—Paraesthesia—Prednisone—multiple sclerosis	8.85e-05	0.000323	CcSEcCtD
Fluvoxamine—Pruritus—Triamcinolone—multiple sclerosis	8.83e-05	0.000322	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—multiple sclerosis	8.81e-05	0.000322	CcSEcCtD
Fluvoxamine—Pruritus—Methylprednisolone—multiple sclerosis	8.81e-05	0.000321	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	8.77e-05	0.00176	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	8.75e-05	0.00176	CbGpPWpGaD
Fluvoxamine—Convulsion—Methotrexate—multiple sclerosis	8.75e-05	0.000319	CcSEcCtD
Fluvoxamine—Dyspepsia—Prednisone—multiple sclerosis	8.68e-05	0.000317	CcSEcCtD
Fluvoxamine—SLC6A4—Circadian rythm related genes—FAS—multiple sclerosis	8.67e-05	0.00174	CbGpPWpGaD
Fluvoxamine—Arthralgia—Methotrexate—multiple sclerosis	8.6e-05	0.000314	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—multiple sclerosis	8.6e-05	0.000314	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—multiple sclerosis	8.6e-05	0.000314	CcSEcCtD
Fluvoxamine—Decreased appetite—Prednisone—multiple sclerosis	8.57e-05	0.000313	CcSEcCtD
Fluvoxamine—Rash—Prednisolone—multiple sclerosis	8.55e-05	0.000312	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisolone—multiple sclerosis	8.55e-05	0.000312	CcSEcCtD
Fluvoxamine—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.53e-05	0.00171	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Methylprednisolone—multiple sclerosis	8.52e-05	0.000311	CcSEcCtD
Fluvoxamine—Fatigue—Prednisone—multiple sclerosis	8.5e-05	0.00031	CcSEcCtD
Fluvoxamine—Headache—Prednisolone—multiple sclerosis	8.5e-05	0.00031	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—multiple sclerosis	8.49e-05	0.00031	CcSEcCtD
Fluvoxamine—Constipation—Prednisone—multiple sclerosis	8.43e-05	0.000308	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—multiple sclerosis	8.31e-05	0.000303	CcSEcCtD
Fluvoxamine—Dizziness—Triamcinolone—multiple sclerosis	8.25e-05	0.000301	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—multiple sclerosis	8.24e-05	0.000301	CcSEcCtD
Fluvoxamine—Dizziness—Methylprednisolone—multiple sclerosis	8.23e-05	0.0003	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	8.19e-05	0.00165	CbGpPWpGaD
Fluvoxamine—Infection—Methotrexate—multiple sclerosis	8.19e-05	0.000299	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisone—multiple sclerosis	8.12e-05	0.000297	CcSEcCtD
Fluvoxamine—Asthenia—Betamethasone—multiple sclerosis	8.12e-05	0.000296	CcSEcCtD
Fluvoxamine—Asthenia—Dexamethasone—multiple sclerosis	8.12e-05	0.000296	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—multiple sclerosis	8.08e-05	0.000295	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—multiple sclerosis	8.07e-05	0.000294	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Prednisone—multiple sclerosis	8.06e-05	0.000294	CcSEcCtD
Fluvoxamine—Nausea—Prednisolone—multiple sclerosis	8.06e-05	0.000294	CcSEcCtD
Fluvoxamine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.03e-05	0.00162	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.03e-05	0.00162	CbGpPWpGaD
Fluvoxamine—Pruritus—Betamethasone—multiple sclerosis	8.01e-05	0.000292	CcSEcCtD
Fluvoxamine—Pruritus—Dexamethasone—multiple sclerosis	8.01e-05	0.000292	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—multiple sclerosis	7.97e-05	0.000291	CcSEcCtD
Fluvoxamine—Vomiting—Triamcinolone—multiple sclerosis	7.93e-05	0.00029	CcSEcCtD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.92e-05	0.00159	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.92e-05	0.00159	CbGpPWpGaD
Fluvoxamine—Vomiting—Methylprednisolone—multiple sclerosis	7.92e-05	0.000289	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—CD86—multiple sclerosis	7.88e-05	0.00159	CbGpPWpGaD
Fluvoxamine—Rash—Triamcinolone—multiple sclerosis	7.87e-05	0.000287	CcSEcCtD
Fluvoxamine—Dermatitis—Triamcinolone—multiple sclerosis	7.86e-05	0.000287	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—multiple sclerosis	7.85e-05	0.000287	CcSEcCtD
Fluvoxamine—Rash—Methylprednisolone—multiple sclerosis	7.85e-05	0.000286	CcSEcCtD
Fluvoxamine—Dermatitis—Methylprednisolone—multiple sclerosis	7.84e-05	0.000286	CcSEcCtD
Fluvoxamine—Urticaria—Prednisone—multiple sclerosis	7.83e-05	0.000286	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	7.82e-05	0.00157	CbGpPWpGaD
Fluvoxamine—Headache—Triamcinolone—multiple sclerosis	7.82e-05	0.000285	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.81e-05	0.00157	CbGpPWpGaD
Fluvoxamine—Headache—Methylprednisolone—multiple sclerosis	7.8e-05	0.000285	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	7.8e-05	0.00157	CbGpPWpGaD
Fluvoxamine—Abdominal pain—Prednisone—multiple sclerosis	7.79e-05	0.000284	CcSEcCtD
Fluvoxamine—Body temperature increased—Prednisone—multiple sclerosis	7.79e-05	0.000284	CcSEcCtD
Fluvoxamine—SLC6A3—Neuronal System—BCHE—multiple sclerosis	7.75e-05	0.00156	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Betamethasone—multiple sclerosis	7.75e-05	0.000283	CcSEcCtD
Fluvoxamine—Diarrhoea—Dexamethasone—multiple sclerosis	7.75e-05	0.000283	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—IL10—multiple sclerosis	7.73e-05	0.00155	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	7.73e-05	0.00155	CbGpPWpGaD
Fluvoxamine—Hypotension—Methotrexate—multiple sclerosis	7.7e-05	0.000281	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—IL4—multiple sclerosis	7.52e-05	0.00151	CbGpPWpGaD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	7.51e-05	0.000274	CcSEcCtD
Fluvoxamine—Dizziness—Dexamethasone—multiple sclerosis	7.49e-05	0.000273	CcSEcCtD
Fluvoxamine—Dizziness—Betamethasone—multiple sclerosis	7.49e-05	0.000273	CcSEcCtD
Fluvoxamine—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.48e-05	0.00151	CbGpPWpGaD
Fluvoxamine—Insomnia—Methotrexate—multiple sclerosis	7.45e-05	0.000272	CcSEcCtD
Fluvoxamine—Nausea—Triamcinolone—multiple sclerosis	7.41e-05	0.000271	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—multiple sclerosis	7.4e-05	0.00027	CcSEcCtD
Fluvoxamine—Nausea—Methylprednisolone—multiple sclerosis	7.39e-05	0.00027	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.35e-05	0.00148	CbGpPWpGaD
Fluvoxamine—Dyspnoea—Methotrexate—multiple sclerosis	7.35e-05	0.000268	CcSEcCtD
Fluvoxamine—CYP2E1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.33e-05	0.00147	CbGpPWpGaD
Fluvoxamine—Somnolence—Methotrexate—multiple sclerosis	7.32e-05	0.000267	CcSEcCtD
Fluvoxamine—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.32e-05	0.00147	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Prednisone—multiple sclerosis	7.26e-05	0.000265	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—multiple sclerosis	7.25e-05	0.000265	CcSEcCtD
Fluvoxamine—Vomiting—Betamethasone—multiple sclerosis	7.2e-05	0.000263	CcSEcCtD
Fluvoxamine—Vomiting—Dexamethasone—multiple sclerosis	7.2e-05	0.000263	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—multiple sclerosis	7.16e-05	0.000261	CcSEcCtD
Fluvoxamine—Rash—Betamethasone—multiple sclerosis	7.14e-05	0.000261	CcSEcCtD
Fluvoxamine—Rash—Dexamethasone—multiple sclerosis	7.14e-05	0.000261	CcSEcCtD
Fluvoxamine—Dermatitis—Dexamethasone—multiple sclerosis	7.13e-05	0.00026	CcSEcCtD
Fluvoxamine—Dermatitis—Betamethasone—multiple sclerosis	7.13e-05	0.00026	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	7.11e-05	0.00026	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—multiple sclerosis	7.1e-05	0.000259	CcSEcCtD
Fluvoxamine—Headache—Betamethasone—multiple sclerosis	7.09e-05	0.000259	CcSEcCtD
Fluvoxamine—Headache—Dexamethasone—multiple sclerosis	7.09e-05	0.000259	CcSEcCtD
Fluvoxamine—Asthenia—Prednisone—multiple sclerosis	7.07e-05	0.000258	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—multiple sclerosis	7.05e-05	0.000257	CcSEcCtD
Fluvoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.98e-05	0.0014	CbGpPWpGaD
Fluvoxamine—Pruritus—Prednisone—multiple sclerosis	6.98e-05	0.000255	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—FAS—multiple sclerosis	6.93e-05	0.00139	CbGpPWpGaD
Fluvoxamine—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.91e-05	0.00139	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	6.89e-05	0.00139	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	6.81e-05	0.00137	CbGpPWpGaD
Fluvoxamine—Feeling abnormal—Methotrexate—multiple sclerosis	6.79e-05	0.000248	CcSEcCtD
Fluvoxamine—Diarrhoea—Prednisone—multiple sclerosis	6.75e-05	0.000246	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—multiple sclerosis	6.74e-05	0.000246	CcSEcCtD
Fluvoxamine—Nausea—Betamethasone—multiple sclerosis	6.72e-05	0.000245	CcSEcCtD
Fluvoxamine—Nausea—Dexamethasone—multiple sclerosis	6.72e-05	0.000245	CcSEcCtD
Fluvoxamine—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	6.68e-05	0.00134	CbGpPWpGaD
Fluvoxamine—Urticaria—Methotrexate—multiple sclerosis	6.55e-05	0.000239	CcSEcCtD
Fluvoxamine—Dizziness—Prednisone—multiple sclerosis	6.52e-05	0.000238	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—multiple sclerosis	6.51e-05	0.000238	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—multiple sclerosis	6.51e-05	0.000238	CcSEcCtD
Fluvoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.42e-05	0.00129	CbGpPWpGaD
Fluvoxamine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.36e-05	0.00128	CbGpPWpGaD
Fluvoxamine—Vomiting—Prednisone—multiple sclerosis	6.27e-05	0.000229	CcSEcCtD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.27e-05	0.00126	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.27e-05	0.00126	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	6.22e-05	0.00125	CbGpPWpGaD
Fluvoxamine—Rash—Prednisone—multiple sclerosis	6.22e-05	0.000227	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	6.21e-05	0.00125	CbGpPWpGaD
Fluvoxamine—Dermatitis—Prednisone—multiple sclerosis	6.21e-05	0.000227	CcSEcCtD
Fluvoxamine—Headache—Prednisone—multiple sclerosis	6.18e-05	0.000225	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	6.17e-05	0.00124	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	6.1e-05	0.00123	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	6.08e-05	0.00122	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Methotrexate—multiple sclerosis	6.07e-05	0.000222	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	5.96e-05	0.0012	CbGpPWpGaD
Fluvoxamine—Asthenia—Methotrexate—multiple sclerosis	5.91e-05	0.000216	CcSEcCtD
Fluvoxamine—Nausea—Prednisone—multiple sclerosis	5.86e-05	0.000214	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—multiple sclerosis	5.83e-05	0.000213	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—SRM—multiple sclerosis	5.8e-05	0.00117	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—CD80—multiple sclerosis	5.75e-05	0.00116	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	5.68e-05	0.00114	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	5.68e-05	0.00114	CbGpPWpGaD
Fluvoxamine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.66e-05	0.00114	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Methotrexate—multiple sclerosis	5.64e-05	0.000206	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	5.59e-05	0.00112	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.45e-05	0.0011	CbGpPWpGaD
Fluvoxamine—Dizziness—Methotrexate—multiple sclerosis	5.45e-05	0.000199	CcSEcCtD
Fluvoxamine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.44e-05	0.00109	CbGpPWpGaD
Fluvoxamine—CYP3A7—Biological oxidations—POMC—multiple sclerosis	5.38e-05	0.00108	CbGpPWpGaD
Fluvoxamine—Vomiting—Methotrexate—multiple sclerosis	5.24e-05	0.000191	CcSEcCtD
Fluvoxamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.2e-05	0.00105	CbGpPWpGaD
Fluvoxamine—Rash—Methotrexate—multiple sclerosis	5.2e-05	0.00019	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—multiple sclerosis	5.19e-05	0.000189	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—multiple sclerosis	5.16e-05	0.000188	CcSEcCtD
Fluvoxamine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.16e-05	0.00104	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.13e-05	0.00103	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.13e-05	0.00103	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.12e-05	0.00103	CbGpPWpGaD
Fluvoxamine—SLC6A4—NRF2 pathway—TGFB1—multiple sclerosis	5.09e-05	0.00102	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	4.99e-05	0.001	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	4.98e-05	0.001	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	4.97e-05	0.001	CbGpPWpGaD
Fluvoxamine—Nausea—Methotrexate—multiple sclerosis	4.89e-05	0.000179	CcSEcCtD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.68e-05	0.00094	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.68e-05	0.00094	CbGpPWpGaD
Fluvoxamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.63e-05	0.000931	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.55e-05	0.000914	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.51e-05	0.000907	CbGpPWpGaD
Fluvoxamine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.41e-05	0.000886	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—SRM—multiple sclerosis	4.29e-05	0.000863	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—SRM—multiple sclerosis	4.2e-05	0.000845	CbGpPWpGaD
Fluvoxamine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.2e-05	0.000844	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—SRM—multiple sclerosis	4.19e-05	0.000843	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	4.09e-05	0.000822	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	4.09e-05	0.000822	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.05e-05	0.000815	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.04e-05	0.000812	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4e-05	0.000804	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4e-05	0.000804	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4e-05	0.000804	CbGpPWpGaD
Fluvoxamine—CYP2B6—Biological oxidations—POMC—multiple sclerosis	3.98e-05	0.0008	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—SRM—multiple sclerosis	3.96e-05	0.000797	CbGpPWpGaD
Fluvoxamine—CYP2E1—Biological oxidations—POMC—multiple sclerosis	3.89e-05	0.000783	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	3.89e-05	0.000782	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—POMC—multiple sclerosis	3.89e-05	0.000781	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.88e-05	0.00078	CbGpPWpGaD
Fluvoxamine—SLC6A3—NRF2 pathway—TGFB1—multiple sclerosis	3.88e-05	0.00078	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	3.88e-05	0.00078	CbGpPWpGaD
Fluvoxamine—SLC6A3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	3.86e-05	0.000777	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.8e-05	0.000765	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GPC5—multiple sclerosis	3.74e-05	0.000752	CbGpPWpGaD
Fluvoxamine—CYP1A1—Biological oxidations—POMC—multiple sclerosis	3.67e-05	0.000738	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.64e-05	0.000732	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.62e-05	0.000728	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.62e-05	0.000728	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.42e-05	0.000688	CbGpPWpGaD
Fluvoxamine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.4e-05	0.000684	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—SRM—multiple sclerosis	3.24e-05	0.000652	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—SRM—multiple sclerosis	3.16e-05	0.000636	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.15e-05	0.000634	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—RRM1—multiple sclerosis	3.1e-05	0.000623	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.07e-05	0.000617	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	3.02e-05	0.000608	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	3.02e-05	0.000608	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3e-05	0.000604	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—SRM—multiple sclerosis	2.98e-05	0.0006	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—IL6—multiple sclerosis	2.97e-05	0.000597	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	2.96e-05	0.000595	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	2.96e-05	0.000595	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.96e-05	0.000595	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SRM—multiple sclerosis	2.96e-05	0.000594	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.95e-05	0.000594	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.95e-05	0.000594	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.94e-05	0.000592	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	2.79e-05	0.000561	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	2.79e-05	0.000561	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.76e-05	0.000556	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.76e-05	0.000556	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.74e-05	0.000551	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.73e-05	0.000549	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.71e-05	0.000545	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GPC5—multiple sclerosis	2.71e-05	0.000545	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.7e-05	0.000543	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GPC5—multiple sclerosis	2.55e-05	0.000513	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SRM—multiple sclerosis	2.53e-05	0.000508	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.34e-05	0.000471	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.29e-05	0.000461	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.28e-05	0.000459	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.28e-05	0.000459	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—MAPK1—multiple sclerosis	2.27e-05	0.000456	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—RRM1—multiple sclerosis	2.24e-05	0.000451	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.24e-05	0.00045	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.23e-05	0.000449	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.23e-05	0.000448	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.23e-05	0.000448	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—RRM1—multiple sclerosis	2.12e-05	0.000425	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.1e-05	0.000422	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.1e-05	0.000422	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.09e-05	0.00042	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.08e-05	0.000419	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.08e-05	0.000419	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GPC5—multiple sclerosis	2.04e-05	0.00041	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.04e-05	0.000409	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.96e-05	0.000395	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.95e-05	0.000392	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.92e-05	0.000386	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.9e-05	0.000383	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.81e-05	0.000363	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.78e-05	0.000358	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.78e-05	0.000358	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.78e-05	0.000358	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.74e-05	0.00035	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.73e-05	0.000348	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—RRM1—multiple sclerosis	1.69e-05	0.00034	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.64e-05	0.00033	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.63e-05	0.000327	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.59e-05	0.00032	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.58e-05	0.000317	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.56e-05	0.000313	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.55e-05	0.000313	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.52e-05	0.000307	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.45e-05	0.000292	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.41e-05	0.000284	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.37e-05	0.000276	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.37e-05	0.000276	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.000271	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.34e-05	0.00027	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.32e-05	0.000265	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—BCHE—multiple sclerosis	1.29e-05	0.000259	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.29e-05	0.000259	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.29e-05	0.000258	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.26e-05	0.000253	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.22e-05	0.000246	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—BCHE—multiple sclerosis	1.21e-05	0.000244	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.15e-05	0.000232	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—APOE—multiple sclerosis	1.07e-05	0.000215	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.05e-05	0.000212	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.05e-05	0.000212	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.05e-05	0.00021	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.04e-05	0.000209	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—BCHE—multiple sclerosis	9.94e-06	0.0002	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.76e-06	0.000196	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—BCHE—multiple sclerosis	9.7e-06	0.000195	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.59e-06	0.000193	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—POMC—multiple sclerosis	9.19e-06	0.000185	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.14e-06	0.000184	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.06e-06	0.000182	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.99e-06	0.000181	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ALB—multiple sclerosis	8.38e-06	0.000169	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.2e-06	0.000165	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—APOE—multiple sclerosis	7.91e-06	0.000159	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—APOE—multiple sclerosis	7.75e-06	0.000156	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—BCHE—multiple sclerosis	7.75e-06	0.000156	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—APOE—multiple sclerosis	7.74e-06	0.000156	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—APOE—multiple sclerosis	7.31e-06	0.000147	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—POMC—multiple sclerosis	6.8e-06	0.000137	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—POMC—multiple sclerosis	6.66e-06	0.000134	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—POMC—multiple sclerosis	6.65e-06	0.000134	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—POMC—multiple sclerosis	6.28e-06	0.000126	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ALB—multiple sclerosis	6.2e-06	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ALB—multiple sclerosis	6.07e-06	0.000122	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ALB—multiple sclerosis	6.06e-06	0.000122	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—APOE—multiple sclerosis	5.98e-06	0.00012	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.98e-06	0.00012	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—APOE—multiple sclerosis	5.84e-06	0.000117	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ALB—multiple sclerosis	5.72e-06	0.000115	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—APOE—multiple sclerosis	5.5e-06	0.000111	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—APOE—multiple sclerosis	5.45e-06	0.00011	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—POMC—multiple sclerosis	5.14e-06	0.000103	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—POMC—multiple sclerosis	5.01e-06	0.000101	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—POMC—multiple sclerosis	4.73e-06	9.5e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—POMC—multiple sclerosis	4.68e-06	9.42e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALB—multiple sclerosis	4.68e-06	9.42e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—APOE—multiple sclerosis	4.66e-06	9.37e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALB—multiple sclerosis	4.57e-06	9.19e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALB—multiple sclerosis	4.31e-06	8.66e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALB—multiple sclerosis	4.27e-06	8.59e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—POMC—multiple sclerosis	4e-06	8.05e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALB—multiple sclerosis	3.65e-06	7.34e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—APOE—multiple sclerosis	3.6e-06	7.23e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—POMC—multiple sclerosis	3.09e-06	6.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALB—multiple sclerosis	2.82e-06	5.66e-05	CbGpPWpGaD
